1,7-萘啶-3-羧酸 | 250674-49-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1,7-萘啶-3-羧酸
• 英文名称: 1,7-naphthyridine-3-carboxylic acid
• CAS: 250674-49-8
• 化学式: C₉H₆N₂O₂
• mdl: MFCD11044184
• 分子量: 174.159
• InChiKey: HJYYQFVLSQWEDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  氯甲基氯磺酸酯 、 1,7-萘啶-3-羧酸 生成 Chloromethyl 1,7-naphthyridine-3-carboxylate
  参考文献：
  名称：

  WO2007/38772

  摘要：

  公开号：
• 作为产物：
  描述：

  (4-甲酰基吡啶-3-基)氨基甲酸叔丁酯 在 lithium hydroxide 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 1,7-萘啶-3-羧酸
  参考文献：
  名称：

  Isoquinoline-6-carboxamides as potent and selective anti-human cytomegalovirus (HCMV) inhibitors

  摘要：

  Structure-activity relationship studies on our newly identified anti-HCMV compounds, the 1,6-naphthyridines led to the identification of isoquinoline-6-carboxamides as potent and selective anti-HCMV agents. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00435-7

文献信息

• [EN] TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLE TRICYCLIQUES UTILES EN TANT QU'INHIBITEURS D'IRAK4
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021011724A1

  公开（公告）日：2021-01-21

  Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X1 and X2 are independently C or N, provided that zero or one of X1 and X2 is N; Ring A represented by the structure is: or; and Q, R1, R2, R3, R4, R6, and p are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

  披露了公式(I)的化合物或其盐或前药，其中：X1和X2独立地为C或N，条件是X1和X2中零个或一个是N；环A由以下结构表示：或；以及Q、R1、R2、R3、R4、R6和p在此定义。还披露了使用此类化合物作为IRAK4调节剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗、预防或减缓炎性和自身免疫疾病，或用于癌症治疗。
• [EN] 1,7-NAPHTHYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,7-NAPHTYRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015014768A1

  公开（公告）日：2015-02-05

  The present invention relates to compounds of general formula (I) wherein R1 is phenyl or pyridinyl, which are optionally substituted by one, two or three substituents, selected from halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano or S(O)2-lower alkyl, or is morpholinyl, dihydropyranyl or piperidinyl, wherein piperidinyl is optionally substituted by halogen, or is C(O)O-lower alkyl; R2 is hydrogen; R3 is hydrogen, lower alkyl substituted by halogen, –(CH2)n-S(O)2-lower alkyl, –(CH2)n- cycloalkyl or –(CH2)n-lower alkoxy; R4 is hydrogen or lower alkyl; n is 0, 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction ("chemobrain"), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及一般式(I)的化合物，其中R1为苯基或吡啶基，可以选择性地被一个、两个或三个取代基所取代，所述取代基包括卤素、被卤素取代的低烷基、低烷氧基、被卤素取代的低烷氧基、氰基或S（O）2-低烷基，或为吗啡啉基，二氢吡喃基或哌啶基，其中哌啶基可以选择性地被卤素取代，或为C（O）O-低烷基；R2为氢；R3为氢，被卤素取代的低烷基，-(CH2)n-S（O）2-低烷基，-(CH2)n-环烷基或-(CH2)n-低烷氧基；R4为氢或低烷基；n为0、1或2；或其药学上可接受的酸加成盐、外消旋体混合物或其对应的对映异构体。这些化合物可用于治疗精神分裂症、强迫症人格障碍、重度抑郁症、双相情感障碍、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、惊恐障碍、帕金森病、痴呆症、阿尔茨海默病、认知障碍、化疗引起的认知功能障碍（“化疗脑”）、唐氏综合征、自闭症谱系障碍、听力损失、耳鸣、脊髓小脑性共济失调、肌萎缩侧索硬化症、多发性硬化症、亨廷顿病、中风以及由放射治疗、慢性应激、视神经病变或黄斑变性、神经活性药物滥用（包括酒精、鸦片、甲基苯丙胺、苯环利定和可卡因）引起的干扰。
• Novel Drugs for Dementia
  申请人：Ternansky Robert

  公开号：US20080227806A1

  公开（公告）日：2008-09-18

  The invention is directed to compounds that are prodrugs containing a chemical delivery system (CDS) moiety and a cysteine protease inhibitor moiety. The CDS moiety targets the prodrug to the brain or central nervous system. The cysteine protease inhibitor inhibits cysteine proteases upon release from the prodrug. Cysteine protease inhibitors are effective for treating dementia, Alzheimer's disease and vascular dementia. Targeting the brain or central nervous system offers significant advantages in treating these conditions and diseases. A preferred CDS prodrug is a dihydrotrigoneline CDS moiety coupled to an epoxysuccinyl peptide cysteine protease inhibitor moiety.

  本发明涉及一种含有化学递送系统（CDS）基团和半胱氨酸蛋白酶抑制剂基团的前药化合物。CDS基团将前药定位于大脑或中枢神经系统。半胱氨酸蛋白酶抑制剂在从前药中释放后抑制半胱氨酸蛋白酶。半胱氨酸蛋白酶抑制剂对治疗痴呆症、阿尔茨海默病和血管性痴呆症有效。定位于大脑或中枢神经系统在治疗这些疾病和症状方面具有显著的优势。首选的CDS前药是将二氢三角线CDS基团与环氧丙酰肽半胱氨酸蛋白酶抑制剂基团耦合。
• G-Protein Coupled Receptor Agonists
  申请人：Fyfe Matthew Colin Thor

  公开号：US20090099227A1

  公开（公告）日：2009-04-16

  Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.

  化合物式（I）或其药学上可接受的盐或N-氧化物，是GPR116激动剂，可用于治疗肥胖症和糖尿病的治疗。
• Brain-penetrant cyanoindane and cyanotetralin inhibitors of G2019S-LRRK2 kinase activity
  作者：Albert W. Garofalo、Jacob Schwarz、Kerry Zobel、Claudia Beato、Silvia Bernardi、Federica Budassi、Laura Caberlotto、Peng Gao、Cristiana Griffante、Xinying Liu、Marco Migliore、Feifei Qiao、Fabio Maria Sabbatini、Anna Sava、Mingliang Zhang、Holly J. Carlisle

  DOI：10.1016/j.bmcl.2023.129487

  日期：2023.10

  The G2019S variant of LRRK2, which causes an increase in kinase activity, is associated with the occurrence of Parkinson’s disease (PD). Potent, mutation-selective, and brain penetrant inhibitors of LRRK2 can suppress the biological effects specific to G2019S-LRRK2 that cause pathogenicity. We report the discovery of a series of cyanoindane and cyanotetralin kinase inhibitors culminating in compound

  LRRK2 的 G2019S 变体会导致激酶活性增加，与帕金森病 (PD) 的发生有关。LRRK2 的强效、突变选择性和脑渗透抑制剂可以抑制 G2019S-LRRK2 特有的导致致病性的生物效应。我们报告了一系列氰茚烷和氰四氢萘激酶抑制剂的发现，最终形成化合物34，该化合物显示出对小鼠大脑中 LRRK2 磷酸化的选择性抑制。这些新型抑制剂可能进一步为未来帕金森病治疗开辟精准医疗之路。